July 17, 2026
5 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subcutaneous Leqembi approved for initiation; long-term stability with treatment indicated
The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according to a press release from the administration. Previously, patients had to begin treatment with an intravenous dose. Researchers conducting a real-world study, presented at the Alzheimer’s Association International Conference, found that most patients remained stable over an
1,241 words~6 min read
